Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma
Abstract
:1. Introduction
2. Materials and Methods
2.1. Antibodies and Reagents
2.2. Cell Viability Assay
2.3. Histone Protein Extraction
2.4. Western Blot Analysis
2.5. Xenograft Study
2.6. Statistical Analysis
3. Results
3.1. CKD-581 Enhances Acetylation of HDAC Target Proteins
3.2. CKD-581 Reduces Cell Viability of B-Cell Lymphoma Cell Lines
3.3. CKD-581 Decreases the Expression of Poor Prognostic Markers in Lymphoma Cells
3.4. CKD-581 Induces DNA Damage in Lymphoma Cells
3.5. CKD-581 Is Active in Animal Models of B-Cell Lymphoma
4. Discussion
5. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Hunt, K.E.; Reichard, K.K. Diffuse large B-cell lymphoma. Arch. Pathol. Lab Med. 2008, 132, 118–124. [Google Scholar] [PubMed]
- Molina, T.J.; Canioni, D.; Copie-Bergman, C.; Recher, C.; Briere, J.; Haioun, C.; Berger, F.; Ferme, C.; Copin, M.C.; Casasnovas, O.; et al. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: Analysis of data from the Groupe d’Etudes des Lymphomes de l’Adulte/lymphoma study association phase III trial LNH 03-2B. J. Clin. Oncol. 2014, 32, 3996–4003. [Google Scholar]
- Sarkozy, C.; Sehn, L.H. Management of relapsed/refractory DLBCL. Best Pract. Res. Clin. Haematol. 2018, 31, 209–216. [Google Scholar] [CrossRef]
- Coiffier, B.; Sarkozy, C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematol. Am. Soc. Hematol. Educ. Program 2016, 2016, 366–378. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Thieblemont, C.; Gisselbrecht, C. Second-line treatment paradigms for diffuse large B-cell lymphomas. Curr. Oncol. Rep. 2009, 11, 386–393. [Google Scholar] [CrossRef] [PubMed]
- Petrich, A.M.; Nabhan, C.; Smith, S.M. MYC-associated and double-hit lymphomas: A review of pathobiology, prognosis, and therapeutic approaches. Cancer 2014, 120, 3884–3895. [Google Scholar] [CrossRef]
- Swerdlow, S.H.; Campo, E.; Pileri, S.A.; Harris, N.L.; Stein, H.; Siebert, R.; Advani, R.; Ghielmini, M.; Salles, G.A.; Zelenetz, A.D.; et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 2016, 127, 2375–2390. [Google Scholar] [CrossRef] [Green Version]
- Li, W.; Gupta, S.K.; Han, W.; Kundson, R.A.; Nelson, S.; Knutson, D.; Greipp, P.T.; Elsawa, S.F.; Sotomayor, E.M.; Gupta, M. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J. Hematol. Oncol. 2019, 12, 73. [Google Scholar] [CrossRef] [Green Version]
- Hu, S.; Xu-Monette, Z.Y.; Tzankov, A.; Green, T.; Wu, L.; Balasubramanyam, A.; Liu, W.M.; Visco, C.; Li, Y.; Miranda, R.N.; et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: A report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 2013, 121, 4021–4031, quiz 4250. [Google Scholar] [CrossRef] [Green Version]
- Johnson, N.A.; Slack, G.W.; Savage, K.J.; Connors, J.M.; Ben-Neriah, S.; Rogic, S.; Scott, D.W.; Tan, K.L.; Steidl, C.; Sehn, L.H.; et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 2012, 30, 3452–3459. [Google Scholar] [CrossRef]
- Islam, S.; Qi, W.; Morales, C.; Cooke, L.; Spier, C.; Weterings, E.; Mahadevan, D. Disruption of Aneuploidy and Senescence Induced by Aurora Inhibition Promotes Intrinsic Apoptosis in Double Hit or Double Expressor Diffuse Large B-cell Lymphomas. Mol. Cancer Ther. 2017, 16, 2083–2093. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mondello, P.; Younes, A. Emerging drugs for diffuse large B-cell lymphoma. Expert Rev. Anticancer Ther. 2015, 15, 439–451. [Google Scholar] [CrossRef] [PubMed]
- Li, Y.; Seto, E. HDACs and HDAC Inhibitors in Cancer Development and Therapy. Cold Spring Harb. Perspect. Med. 2016, 6, a026831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Wang, M.; Fang, X.; Wang, X. Emerging role of histone deacetylase inhibitors in the treatment of diffuse large B-cell lymphoma. Leuk Lymphoma 2020, 61, 763–775. [Google Scholar] [CrossRef]
- Cortiguera, M.G.; Garcia-Gaipo, L.; Wagner, S.D.; Leon, J.; Batlle-Lopez, A.; Delgado, M.D. Suppression of BCL6 function by HDAC inhibitor mediated acetylation and chromatin modification enhances BET inhibitor effects in B-cell lymphoma cells. Sci. Rep. 2019, 9, 16495. [Google Scholar] [CrossRef]
- Cho, H.; Yoon, D.H.; Kim, K.P.; Bae, K.S.; Kim, W.S.; Eom, H.S.; Kim, J.S.; Hong, J.Y.; Kim, S.J.; Lee, H.; et al. Phase I study of CKD-581, a pan-histone deacetylase inhibitor, in patients with lymphoma or multiple myeloma refractory to standard therapy. Investig. New Drugs 2018, 36, 877–885. [Google Scholar] [CrossRef] [PubMed]
- Kim, H.-J.; Bae, S.-C. Histone deacetylase inhibitors: Molecular mechanisms of action and clinical trials as anti-cancer drugs. Am. J. Transl. Res. 2011, 3, 166–179. [Google Scholar]
- Deng, W.; Clipson, A.; Liu, H.; Huang, Y.; Dobson, R.; Wang, M.; Johnson, P.; Du, M.Q. Variable Responses of MYC Translocation Positive Lymphoma Cell Lines To Different Combinations of Novel Agents: Impact of BCL2 Family Protein Expression. Transl. Oncol. 2018, 11, 1147–1154. [Google Scholar] [CrossRef]
- Mullen, P. PARP cleavage as a means of assessing apoptosis. Methods Mol. Med. 2004, 88, 171–181. [Google Scholar]
- Adams, C.M.; Clark-Garvey, S.; Porcu, P.; Eischen, C.M. Targeting the Bcl-2 Family in B Cell Lymphoma. Front. Oncol. 2018, 8, 636. [Google Scholar] [CrossRef]
- Kelly, P.N.; Grabow, S.; Delbridge, A.R.; Strasser, A.; Adams, J.M. Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 2011, 118, 6380–6386. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Kelly, G.L.; Grabow, S.; Glaser, S.P.; Fitzsimmons, L.; Aubrey, B.J.; Okamoto, T.; Valente, L.J.; Robati, M.; Tai, L.; Fairlie, W.D.; et al. Targeting of MCL-1 kills MYC-driven mouse and human lymphomas even when they bear mutations in p53. Genes Dev. 2014, 28, 58–70. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Linden, M.; Kirchhof, N.; Carlson, C.; Van Ness, B. Targeted overexpression of Bcl-XL in B-lymphoid cells results in lymphoproliferative disease and plasma cell malignancies. Blood 2004, 103, 2779–2786. [Google Scholar] [CrossRef] [Green Version]
- Zhou, P.; Levy, N.B.; Xie, H.; Qian, L.; Lee, C.Y.; Gascoyne, R.D.; Craig, R.W. MCL1 transgenic mice exhibit a high incidence of B-cell lymphoma manifested as a spectrum of histologic subtypes. Blood 2001, 97, 3902–3909. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Stolz, C.; Hess, G.; Hahnel, P.S.; Grabellus, F.; Hoffarth, S.; Schmid, K.W.; Schuler, M. Targeting Bcl-2 family proteins modulates the sensitivity of B-cell lymphoma to rituximab-induced apoptosis. Blood 2008, 112, 3312–3321. [Google Scholar] [CrossRef] [PubMed]
- Thompson, R.C.; Vardinogiannis, I.; Gilmore, T.D. The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity. PLoS ONE 2013, 8, e62822. [Google Scholar] [CrossRef] [Green Version]
- Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: Targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15, 1126–1132. [Google Scholar] [CrossRef] [Green Version]
- Xiang, W.; Yang, C.Y.; Bai, L. MCL-1 inhibition in cancer treatment. Oncol. Targets Ther. 2018, 11, 7301–7314. [Google Scholar] [CrossRef] [Green Version]
- Coiffier, B.; Haioun, C.; Ketterer, N.; Engert, A.; Tilly, H.; Ma, D.; Johnson, P.; Lister, A.; Feuring-Buske, M.; Radford, J.A.; et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998, 92, 1927–1932. [Google Scholar]
- Feugier, P.; Van Hoof, A.; Sebban, C.; Solal-Celigny, P.; Bouabdallah, R.; Ferme, C.; Christian, B.; Lepage, E.; Tilly, H.; Morschhauser, F.; et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d’Etude des Lymphomes de l’Adulte. J. Clin. Oncol. 2005, 23, 4117–4126. [Google Scholar] [CrossRef] [Green Version]
- Mohammed, R.; Milne, A.; Kayani, K.; Ojha, U. How the discovery of rituximab impacted the treatment of B-cell non-Hodgkin’s lymphomas. J. Blood Med. 2019, 10, 71–84. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Duvic, M.; Talpur, R.; Ni, X.; Zhang, C.; Hazarika, P.; Kelly, C.; Chiao, J.H.; Reilly, J.F.; Ricker, J.L.; Richon, V.M.; et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007, 109, 31–39. [Google Scholar] [CrossRef] [PubMed]
- Ellis, L.; Pan, Y.; Smyth, G.K.; George, D.J.; McCormack, C.; Williams-Truax, R.; Mita, M.; Beck, J.; Burris, H.; Ryan, G.; et al. Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma. Clin. Cancer Res. 2008, 14, 4500–4510. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gore, L.; Rothenberg, M.L.; O’Bryant, C.L.; Schultz, M.K.; Sandler, A.B.; Coffin, D.; McCoy, C.; Schott, A.; Scholz, C.; Eckhardt, S.G. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. Clin. Cancer Res. 2008, 14, 4517–4525. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Vansteenkiste, J.; Van Cutsem, E.; Dumez, H.; Chen, C.; Ricker, J.L.; Randolph, S.S.; Schoffski, P. Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Investig. New Drugs 2008, 26, 483–488. [Google Scholar] [CrossRef] [PubMed]
- Egorin, M.J.; Yuan, Z.M.; Sentz, D.L.; Plaisance, K.; Eiseman, J.L. Plasma pharmacokinetics of butyrate after intravenous administration of sodium butyrate or oral administration of tributyrin or sodium butyrate to mice and rats. Cancer Chemother. Pharmacol. 1999, 43, 445–453. [Google Scholar] [CrossRef]
- Gore, S.D.; Weng, L.J.; Zhai, S.; Figg, W.D.; Donehower, R.C.; Dover, G.J.; Grever, M.; Griffin, C.A.; Grochow, L.B.; Rowinsky, E.K.; et al. Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin. Cancer Res. 2001, 7, 2330–2339. [Google Scholar] [PubMed]
- Wu, M.; Sirota, M.; Butte, A.J.; Chen, B. Characteristics of drug combination therapy in oncology by analyzing clinical trial data on ClinicalTrials.gov. Pac. Symp. Biocomput. 2015, 68–79. [Google Scholar] [CrossRef] [Green Version]
- Bayat Mokhtari, R.; Homayouni, T.S.; Baluch, N.; Morgatskaya, E.; Kumar, S.; Das, B.; Yeger, H. Combination therapy in combating cancer. Oncotarget 2017, 8, 38022–38043. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Imai, Y.; Hirano, M.; Kobayashi, M.; Futami, M.; Tojo, A. HDAC Inhibitors Exert Anti-Myeloma Effects through Multiple Modes of Action. Cancers 2019, 11, 475. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amengual, J.E.; Johannet, P.; Lombardo, M.; Zullo, K.; Hoehn, D.; Bhagat, G.; Scotto, L.; Jirau-Serrano, X.; Radeski, D.; Heinen, J.; et al. Dual Targeting of Protein Degradation Pathways with the Selective HDAC6 Inhibitor ACY-1215 and Bortezomib Is Synergistic in Lymphoma. Clin. Cancer Res. 2015, 21, 4663–4675. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amengual, J.E.; Prabhu, S.A.; Lombardo, M.; Zullo, K.; Johannet, P.M.; Gonzalez, Y.; Scotto, L.; Serrano, X.J.; Wei, Y.; Duong, J.; et al. Mechanisms of Acquired Drug Resistance to the HDAC6 Selective Inhibitor Ricolinostat Reveals Rational Drug-Drug Combination with Ibrutinib. Clin. Cancer Res. 2017, 23, 3084–3096. [Google Scholar] [CrossRef] [PubMed] [Green Version]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Kim, S.J.; Kim, U.J.; Yoo, H.Y.; Choi, Y.J.; Kang, K.W. Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma. Int. J. Mol. Sci. 2020, 21, 4377. https://doi.org/10.3390/ijms21124377
Kim SJ, Kim UJ, Yoo HY, Choi YJ, Kang KW. Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma. International Journal of Molecular Sciences. 2020; 21(12):4377. https://doi.org/10.3390/ijms21124377
Chicago/Turabian StyleKim, Soo Jin, U Ji Kim, Hae Yong Yoo, Yong June Choi, and Keon Wook Kang. 2020. "Anti-Cancer Effects of CKD-581, a Potent Histone Deacetylase Inhibitor against Diffuse Large B-Cell Lymphoma" International Journal of Molecular Sciences 21, no. 12: 4377. https://doi.org/10.3390/ijms21124377